A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

Published:2011-01 Issue:1 Volume:13 Page:74-84
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Su Zengliu,Dias-Santagata Dora,Duke MarKeesa,Hutchinson Katherine,Lin Ya-Lun,Borger Darrell R.,Chung Christine H.,Massion Pierre P.,Vnencak-Jones Cindy L.,Iafrate A. John,Pao William

Funder

NIH/National Cancer Institute

VICC Specialized Program of Research Excellence in Lung Cancer

Vanderbilt-Ingram Cancer Center Core

V Foundation

TJ Martell Foundation

Kleberg Foundation

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference38 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2009

3. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma;Marks;Cancer Res,2008

4. Genetic predictors of MEK dependence in non-small cell lung cancer;Pratilas;Cancer Res,2008

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;CLIN LUNG CANCER;2024

2. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;Clinical Lung Cancer;2024-09

3. Detection of RAS p.Q61R by Immunohistochemistry in Practice: A Clinicopathologic Study of 217 Thyroid Nodules with Molecular Correlates;Endocrine Pathology;2024-08-03

4. Panel Sequencing for Targeted Therapy Selection in Solid Tumors;Clinics in Laboratory Medicine;2022-09

5. Clinical Significance of Expression of Periostin in Non-small Cell Lung Cancer;Journal of the College of Physicians and Surgeons Pakistan;2022-09-01